HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 277, Issue 19, 17125-17138, May 10, 2002

This Article Abstract Full Text (PDF) All Versions of this Article: 277/19/17125    most recent M109250200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mann, J. Articles by Mann, D. A. Search for Related Content PubMed PubMed Citation Articles by Mann, J. Articles by Mann, D. A. Social Bookmarking                      What's this?

CD40 Induces Interleukin-6 Gene Transcription in Dendritic Cells

REGULATION BY TRAF2, AP-1, NF-B, AND CBF1^*

Jelena Mann^§, Fiona Oakley, Peter W. M. Johnson^§, and Derek A. Mann^¶

From the  Division of Infection, Inflammation and Repair and ^§ Division of Cancer Sciences, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom

Received for publication, September 25, 2001, and in revised form, February 28, 2002

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

CD40-induced activation of cytokine gene expression in dendritic cells (DC) is an important process in the initiation of primary immune responses. We have determined the intracellular signaling events that lead to CD40 ligation-induced activation of interleukin-6 (IL-6) gene transcription in a murine DC line, FSDC, that is phenotypically representative of bone marrow-derived DC. IL-6 reverse transcriptase-PCR and promoter assays established the responsiveness of FSDC to anti-CD40 ligation. Further promoter assays showed that the transcription factors NF-B and AP-1 are downstream transcriptional mediators of CD40-induced IL-6 gene expression. Anti-CD40 treatment of FSDC stimulated increased expression of specific NF-B (p50:p65) and AP-1 (c-Jun, JunB, JunD, and c-Fos) DNA-protein complexes. Overexpression of an IB- super-repressor or a dominant negative JunD resulted in a strong inhibition of CD40-inducible IL-6 promoter activity supporting a role for both transcription factors. Upstream signal transduction events were studied by transfection of wild type and mutant human CD40 expression constructs into FSDC followed by stimulation with an anti-human CD40 antibody. These experiments revealed that anti-CD40 stimulation of NF-B and IL-6 gene transcription requires specific amino acid residues in the cytoplasmic region of CD40 involved in the recruitment of TRAF2. Induction of IL-6 mRNA by anti-CD40 treatment was found to be a transient event (24 h) and was followed by a diminution of IL-6 transcript to levels below those found in unstimulated cells. This loss of IL-6 expression was associated with reduced p50:p65 NF-B DNA binding and elevated binding of CBF1 to a site overlapping the NF-B site. Overexpression of CBF1 resulted in a profound inhibition of basal and anti-CD40-induced IL-6 promoter activities indicating that prolonged induction of CBF1 may contribute to the transient nature of the IL-6 response. The physiological relevance of these molecular events to DC function is discussed.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Dendritic cells (DCs)¹ are antigen presenting cells that are specialized to have the unique property of being able to prime naive T cells. The powerful immunogenic properties of DCs have implicated these cells in the abrogation of peripheral T cell tolerance against viral, microbial, tumor, and transplant antigens (1). Following antigen capture the immature DC undergoes phenotypic and functional changes that promote its antigen presenting cells characteristics (1). Maturation events involving migration to the lymph nodes, alteration of intracellular major histocompatibility class II transport and surface expression, and decreased capacity to take up and process antigen are required for the DC to be able to activate T cells (1). Interaction of CD40 on DCs with CD40 ligand (CD40L) on naive T cells is critical for DC maturation and the generation of antigen-specific T cell responses (1, 2). CD40L promotes DC survival, elevates expression of major histocompatibility and co-stimulatory molecules, and induces the expression of a variety of cytokines including tumor necrosis factor, IL-1, IL-6, IL-12, IL-15, and IL-18, all of which are involved in T cell activation and proliferation (1, 2).

IL-6 is a highly pleiotropic cytokine with properties that indicate it is not only a stimulator of the activation, proliferation, and survival of T cells (3-9), but is also able to modify DC function and survival (1, 10, 11). A direct effect of IL-6 on the proliferation of T cells has been documented by several groups (3-8), as has the ability of IL-6 to prevent the death of naive T cells (9). Other studies have described the ability of IL-6 to induce IFN secretion in differentiating T cells; indeed lack of this response in IL-6 gene knockout mice renders animals unable to mount T cell responses against Mycobacterium. tuberculosis and Toxoplasma gonddi (12, 13). Production of IL-6 by CD40-stimulated DCs (1, 11) is therefore likely to be important in promoting the generation and survival of antigen-specific cytotoxic T cells. IL-6 can alter the manner in which antigen is processed by DCs enabling the activation of T cells against determinants that were previously cryptic (10). In addition, Grohmann and colleagues (11) reported that autocrine IL-6 mediates most of the anti-tolerogenic effects of CD40 ligation on CD8⁺ DC. Aberrant regulation of autocrine and paracrine stimulation of DCs by IL-6 may therefore be important in the generation of anti-self immunity and propagation of autoimmune disease.

The signal transduction events leading to the activation of cytokine gene transcription by stimulation of CD40 have mainly been studied in B cells. By contrast little is understood about these events in other cell types, including DCs (2). Studies regarding the transcriptional regulation of IL-6 in response to engagement of cell surface CD40 by either CD40L or anti-CD40 have so far revealed a potential role for NF-B and the requirement for amino acids 202 to 225 in the cytoplasmic tail of CD40 (14). These amino acids in combination with other motifs in the cytoplasmic tail of CD40 are responsible for the recruitment of Janus kinase 3 (Jak3) and several members of the tumor necrosis factor receptor-associated factor (TRAF) protein family (2, 14-21). These factors function to link CD40 to the signaling pathways that activate NF-B, c-Jun NH₂-terminal kinase (JNK), and STAT3, which in turn stimulate transcription of various CD40-responsive genes. Studies in a variety of cell types have shown that induction of IL-6 gene transcription involves the coordinated regulation of factors that associate with the evolutionary conserved AP-1, NF-B, and NF-IL-6 sites in the mouse and human IL-6 gene promoters (22-27). Similar detailed studies on the promoter and transcription factor requirements for stimulation of IL-6 gene transcription following CD40 engagement are currently lacking. Since there is also a general scarcity of information regarding the transcriptional regulation of DC function, we have therefore undertaken a detailed investigation into events at both the IL-6 promoter and the cytoplasmic tail of CD40 that mediate induction of IL-6 mRNA synthesis in response to CD40 engagement.

Using the murine DC line FSDC (28), we show that anti-CD40 treatment of cells leads to a powerful, but transient induction of IL-6 mRNA expression. We delineate the structural features of the IL-6 promoter required for this response and in addition to demonstrating CD40 induction of AP-1 and NF-B DNA binding activities we also define a role for specific members of these transcription factor families and their inhibitors in the IL-6 response. Finally, co-transfection of the IL-6 promoter with expression vectors for wild type or mutant human CD40 proteins was employed to map amino acid residues in the cytoplasmic tail of CD40 that are required for activation of NF-B and induction of IL-6 mRNA synthesis.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Cell Culture-- FSDC cell line (28), DC2.4 cell line (29), and bone marrow-derived dendritic cells (BMDC) were cultured in RPMI 1640 medium, supplemented with 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine, and 10% fetal calf serum (Invitrogen). BMDC were obtained by extracting bone marrow from the leg bone of Balb/c mice (Harlan UK, Blackthorn, UK). The cells obtained were washed twice in sterile phosphate-buffered saline and plated out onto tissue culture dishes. Cells were grown in complete media supplemented with 5 ng/ml granulocyte macrophage-colony-stimulating factor (30). Media was changed on alternating days for 10 days. Cells were used in studies on day 10 of primary culture.

CD40 Antibodies-- Rat monoclonal antibody 3/23 was raised against mouse CD40 (31). Mouse anti-human CD40 monoclonal antibody LOB7.6 was obtained from Serotec, UK.

Plasmid DNA-- All plasmid DNA was prepared using a commercial DNA extraction and isolation kit (Maxiprep, Qiagen). IL-6 promoter function was studied using the luciferase reporter vector pIL6-Luc651, containing nucleotides 651 to +1 of the human IL-6 gene. Construction of pIL6-Luc651 and derivatives carrying site-directed mutations in the AP-1 (283 to 276), NF-IL6 (154 to 146), and NF-B (72 to 63) sequences have been described elsewhere (26). A luciferase reporter vector containing nucleotides 332 to +35 of the human IB- gene promoter was provided by Professor Ron Hay (St. Andrews, UK). The control Renilla luciferase vector pRL-TK was purchased from Promega (Southampton, UK). An expression vector (pRSV-JunD) for dominant negative JunD lacking amino acids 1-162 has been previously described (27). Expression vector pJH282 for CBF1 was obtained from Dr. Diane Hayward (Baltimore, MD). Dominant negative TRAF2 was produced from an expression vector obtained from Professor David Brenner (Chapel Hill, NC) that generates a TRAF2 protein lacking nucleotides 87-501 which prevents interactions with downstream effector molecules (32). Dominant negative TRAF6 was overexpressed from a vector provided by Professor Luke O'Neill (33). An expression vector encoding an IB super-repressor protein (IBD) has been described elsewhere (34). Wild type human CD40 (hCD40) was amplified from Raji cell line cDNA using h40HindIIIF 5'-ccaagcttcacctcgccatggttcgtctgc-3' sense and h40XbaIR 5'-gtgggtctagactcactgtctctcctgcac-3' antisense primer which incorporate HindIII and XbaI restriction enzyme sites to allow for cloning of hCD40 into pcDNA3 expression vector. Human CD40 expression constructs were generated by two-step recombinant PCR using hCD40 wild type as template for hCD40KKV, hCD40T254A, and hCD40T254S whereas both hCD40 and hCD22 (a gift of Professor Martin Glennie, Southampton, UK) expression constructs were used as templates for generation of hCD40/hCD22 chimeric protein. The general method for two-step recombinant PCR was as follows; first step PCR was constructed as two separate reactions. Reaction 1 was set up using h40HindIIIF primer and the appropriate antisense primer for the given mutant as listed in Table I. In all reactions we used 1 µg of hCD40wt/pcDNA3 template, 100 ng of h40HindIIIF primer, and 100 ng of appropriate antisense primer, 2.5 µl of optimized Pfu polymerase buffer (Promega), 0.4 mM dNTP mixture, and 2 units of Pfu polymerase in a total reaction volume of 25 µl. Reaction 2 was set up in the same manner using h40XbaIR primer and the appropriate sense primer for the given mutant as listed in Table I. In each case both the sense and antisense primers carry the required mutation or a stop codon (as for hCD40KKV). For all first step reactions hCD40wt/pcDNA3 was used as template, except for reaction 2 of hCD40/hCD22 where hCD22 expression construct was used instead. PCR was carried with an initial 5-min incubation at 94 °C. This was followed by 30 cycles of a 1-min annealing step at temperatures outlined in Table I, a 2-min elongation step at 72.0 °C, and a 45-s denaturation step at 94 °C. After 30 cycles a final elongation reaction was carried out for 10 min at 72.0 °C. PCR products were separated by electrophoresis at 80 V for 60 min through a 1% agarose gel and detected by ethidium bromide staining. Expected sizes of specific PCR products (as in Table I) were verified by reference to a 1-kilobase DNA ladder. PCR products were then excised from agarose gels, purified, and eluted in 20 µl of dH₂O. The second step PCR reaction was set up using 10 µl of each of the first step PCR reactions, 2.5 µl of optimized Pfu polymerase buffer (Promega), 0.4 mM dNTP mixture, and 2 units of Pfu polymerase in a total reaction volume of 25 µl. The PCR program was set up as described for first step reactions, with annealing temperature as shown in Table I for each mutant. A total number of 15 cycles was used, followed by addition of h40HindIIIF and h40XbaIR end primers and further 15 PCR cycles. The PCR products were digested with HindIII and XbaI, separated on 1% agarose gel, excised, purified, and ligated into pcDNA3. Presence of the required mutation was confirmed by sequencing. Human CD40 expression constructs hCD40T254E, hCD40T254A262, and hCD40262 were a gift from Professor Lawrence Young (Institute for Cancer Studies, University of Birmingham, UK).

EMSA-- NF-B and AP-1 DNA binding was determined by EMSA as previously described (27) using a ³²P end-labeled double-stranded oligonucleotide probe containing a consensus NF-B or AP1 site as contained within the human IL-6 promoter sequence. NF-B sense oligonucleotide was: 5'-caaatgtgggattttcccatga-3'; and antisense oligonucleotide, 5'-tcatgggaaaatcccacatttg-3'; AP1 sense oligonucleotide was 5'-aaagtgctgagtcactaataa-3', and antisense nucleotide 5'-ttattagtgactcagcacttt-3'. Nuclear extracts were prepared from FSDCs by a protocol modified from that described by Dignam et al. (35). Harvested cells were washed twice in ice-cold phosphate-buffered saline prior to lysis in Buffer A supplemented with 0.2% Nonidet P-40, 0.5 mM 4-(2-aminoethyl)benzenesulfonyl fluoride, 0.2 mM EDTA, and 15 µg/ml aprotinin. Lysates were centrifuged for 10 s at 13,000 rpm to collect crude nuclear pellets. Supernatants were discarded and pellets were washed twice in lysis buffer prior to resuspension in Buffer C supplemented with 0.5 mM 4-(2-aminoethyl)benzenesulfonyl fluoride, 0.2 mM EDTA, and 15 µg/ml aprotinin. After a 10-min incubation on ice with occasional vortexing, the extracts were cleared of insoluble nuclear material by centrifugation at 13,000 rpm for 30 s. Cleared nuclear extracts were transferred to fresh Eppendorf tubes, and their protein content was determined using the Bradford DC assay kit (Bio-Rad). EMSA reactions were assembled on ice and consisted of an initial 10-min incubation of 4 µl of Buffer C containing 2-10 µg of nuclear protein extract and 12 µl of water containing 2 µg of poly(dI-dC). 4 µl of water containing 0.4 ng of radiolabeled double-stranded AP-1 probe was then added to the reaction and, after mixing, was incubated for a further 20 min. For supershift assays, reactions were incubated for a further 16 h in the presence of 2 µg of anti p50/p65 or anti-Jun antiserum (Santa Cruz Biotechnology, Inc.). EMSA and supershift reaction mixtures were then resolved by electrophoresis on an 8% nondenaturing polyacrylamide gel (37:5:1).

SDS-Polyacrylamide Gel Electrophoresis and Immunoblotting-- Crude Nonidet P-40 soluble cytoplasmic extracts were prepared by lysis of phosphate-buffered saline-washed cultures in Dignam buffer A supplemented with 0.2% Nonidet P-40. Lysates were centrifuged for 5 s at 13,000 rpm to collect nuclei. Supernatants were transferred to fresh Eppendorf tubes and centrifuged for a further 1 min at 13,000 rpm to pellet Nonidet P-40 insoluble material, supernatants were then designated as crude cytoplasmic extracts. Nuclear extracts were prepared as described for EMSA reactions. 30 µg of cytoplasmic or nuclear extracts from untreated FSDCs or treated with 30 µg/ml anti-mouse CD40 3/23 mAb were then fractionated by electrophoresis through a 9% SDS-polyacrylamide gel. Gels were run at a 100 V for 1.5 h prior to transfer onto nitrocellulose as previously described (27). Following blockade of nonspecific protein binding, nitrocellulose blots were incubated for 1 h with primary antibodies (diluted in TBS/Tween 20 (0.075%)) containing 3% Marvel and 3% bovine serum albumin. Rabbit polyclonal antibodies recognizing JunD, JunB, and c-Jun (Santa Cruz Biotechnology, Inc.) were used at a final concentration of 1 µg/ml. Blots were then washed three times in TBS/Tween 20 prior to incubation for 1 h with sheep anti-rabbit horseradish peroxidase antibody (1:2000). After extensive washing in TBS/Tween 20 the blots were processed to distilled water for detection of antigen using the ECL system (Amersham Biosciences, Buckinghamshire, United Kingdom).

Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-- mRNA was extracted from 1 × 10⁷ FSDC cells which were either left untreated or were treated with 30 µg/ml anti-mCD40 mAb 3/23 for 24, 48, and 72 h using the "Quickprep micro mRNA Purification kit" (Amersham Biosciences) as per the manufacturer's instructions. 5 µg of mRNA obtained was used to generate first strand cDNA using random hexamer primer (p(dN)₆) and "First strand cDNA synthesis system" (Amersham Biosciences) as per the manufacturer's instructions. PCR amplification of mouse IL-6, IL-12 (p35 and p40), IL-4, IFN, TRAF2, TRAF6, and -actin cDNAs was carried out using specific oligonucleotide primers selected within the coding regions of the genes. IL-6 primers used were 5'-actgatgctggtgacaac- 3' (sense) and 5'-tccacaaactgatatgct-3' (antisense) designed to produce a 620-bp product; IL12p35 primers were 5'-ataaccatgggtctcccaaggtca-3' (sense) and 5'-gccttactagttcaggcggagctc-3' (antisense) designed to produce a 739-bp product; IL12p40 primers were 5'-agcaccatgggtcctcagaagcta-3' (sense) and 5'-cgtactagtctaggatcggaccctgca-3' (antisense) designed to produce a 1007-bp product; IFN primers were 5'-ggccatggtctgagacaatgaacg-3' (sense) and 5'-cctctagagaatcagcagcgactc-3' (antisense) designed to produce a 488-bp product; IL-4 primers were 5'-acagagctattgatgggtctcaacc-3' (sense) and 5'-tttccaggaagtctttcagtgatgt-3' (antisense) designed to produce a 400-bp product; TRAF2 primers were 5'-atgaaggcctgtatgaagaag-3' (sense) and 5'-ttctcagtctccaccatctct-3' (antisense) designed to produce a 472-bp product; TRAF6 primers were 5'-gaaagatgacagcgtgagtgg-3' (sense) and 5'-cacggacgcaaagcaaggtta-3' (antisense) designed to produce a 768-bp product; and -actin primers were 5'-tggaatcctgtggcatccat-3' (sense) and 5'-taaaacgcagctcagtaaca-3' (antisense) designed to produce a 500-bp product. PCRs were composed of 1 µl of cDNA template, 100 ng each of sense and antisense oligonucleotide primers, 2.5 µl of optimized TaqPCR buffer (Promega), 0.4 mM dNTP mixture, and 2 units of Taq polymerase in a total reaction volume of 25 µl. Following an initial 5-min incubation at 94 °C, PCRs were performed using a 1-min annealing step (at 50 °C for IL-6, 59 °C for IL12p35, 57.5 °C for IL12p40, 54 °C for IL-10, 56 °C for IFN and IL-4, 55.7 °C for TRAF2, 55.4 °C for TRAF6, and 55 °C for -actin), followed by a 2-min elongation step at 72.0 °C and a 45-s denaturation step at 94 °C. A total number of 27, 30, 30, 35, 35, 35, 35, and 27 PCR cycles were carried out for detection of IL-6, IL12p35, IL12p40, IFN, IL-4, TRAF2, TRAF6, and -actin, respectively, followed by a final elongation reaction for 10 min at 72.0 °C. PCR products were separated by electrophoresis at 80 V for 60 min through a 1% agarose gel and were detected by ethidium bromide staining. Expected sizes of specific PCR products (620, 739, 1007, 488, 400, 472, 768, and 500 bp for IL-6, IL12p35, IL12p40, IFN, IL-4, TRAF2, TRAF6, and -actin, respectively) were verified by reference to a 1-kilobase DNA ladder.

Transfections and Reporter Gene Assays-- FSDCs and DC2.4s were transfected by the non-liposomal Effectene protocol (Qiagen) according to the manufacturer's instructions. Luciferase assays were performed using a dual luciferase kit (Promega) according to the manufacturer's instructions. IL-6 promoter-driven expression of firefly luciferase was normalized for differences in transfection efficiency by measurement of the activity of a co-transfected Renilla luciferase vector (pRLTK).

	RESULTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

CD40-stimulated Induction of Cytokine mRNAs in Primary Immature Murine Bone Marrow-derived DCs and FSDCs-- To circumvent problems associated with heterogeneity of isolated primary DCs and to generate sufficient cell numbers to perform an in depth analysis of CD40 regulation of IL-6 gene transcription in DCs we used an established cell line. FSDC were originally generated by retroviral-mediated immortalization of DC progenitors from fetal mouse skin and resemble immature BMDC in terms of their morphology, function, and antigenic phenotype (28). Prior to use of FSDC for gene transcription studies we established by fluorescence-activated cell sorter analysis that FSDC express surface CD40 (data not shown). We then determined the relative ability of primary immature murine BMDC and FSDC to express a variety of cytokine transcripts in response to stimulation for 24 h with an anti-mouse CD40 mAb (3/23). Fig. 1 shows RT-PCR analysis of IL-6, IL-12 (p35 and p40), IFN, and IL-4 in unstimulated () and anti-CD40 stimulated (+) BMDC or FSDC. The data show a similar profile for cytokine mRNA expression in BMDC and FSDC with both cells undergoing a strong induction of IL-6 and both the p35 and p40 subunits of IL-12, by contrast neither of the two cell cultures displayed expression of IFN or IL-4. These data suggest that FSDC are a good model for studying the transcriptional induction of IL-6 gene expression by engagement of CD40.

View larger version (44K): [in this window] [in a new window]   Fig. 1.   Induction of cytokines in FSDCs and BMDCs during culture with anti-CD40 mAb 3/23. mRNA was isolated from FSDCs or BMDCs which were either incubated with 30 µg/ml anti-CD40 mAb 3/23 or left untreated for 24 h. The mRNA was used to obtain first strand cDNA, which was used as a template in RT-PCR reactions using protocols described under "Materials and Methods." Utilizing this method, cDNA species encoding murine IL-6, IL-12 (p35 and p40), IFN, IL-4, and -actin were amplified. For IFN and IL-4, positive control RT-PCR reactions are shown on the far left-hand side and used mRNA extracted from total blood lymphocytes (TBL) taken from a Balb/c mouse. The gels shown are representative of at least two independent experiments. A 1-kilobase DNA ladder was run alongside the PCR products to confirm correct sizes of the amplified cDNA fragments.

Requirement for AP1, NF-B, and NF-IL-6 Sites for CD40 Induction of IL-6 Promoter Activity in FSDC-- FSDC were transfected with wild type and mutant IL-6-promoter-luciferase constructs together with a control TK-renilla-luciferase vector to normalize data for differences in transfection efficiency. The mutant IL-6 promoter constructs lacked binding sites for AP1, NF-B, NF-IL-6, or NF-B + NF-IL-6 and have recently been described elsewhere (26, 27). The IL-6 promoter had a weak basal level of transcription that was induced by 20.5-fold in cells stimulated for 24 h with anti-CD40 (fig 2, A and B). These basal and inducible promoter activities therefore reflect the IL-6 mRNA expression data presented in Fig. 1. Mutation of the NF-B site in the IL-6 promoter reduced both basal and CD40-induced transcription such that fold induction in response to anti-CD40 was just 6.4-fold (Fig. 2, A and B). Disruption of NF-IL-6 binding to the promoter mainly affected basal transcription, with the induction in response to CD40 at 24.5-fold being higher than for the wild type promoter. However, a double mutation that perturbed both NF-B and NF-IL-6 binding almost completely abolished the ability of anti-CD40 to induce promoter activity (1.5-fold). These data indicate that NF-B and NF-IL-6 may act in synergy to regulate CD40 signaling at the IL-6 promoter. Mutagenesis of the AP1 site in the IL-6 promoter had a minor effect on basal transcription but reduced anti-CD40-inducible promoter activity to 11-fold, which is almost a 50% reduction of transcription relative to the wild type promoter. Induction of high level IL-6 gene transcription in FSDC by engagement of surface CD40 therefore requires all three transcription factor binding motifs in the IL-6 promoter.

View larger version (18K): [in this window] [in a new window]   Fig. 2.   Induction of IL-6 promoter activity by anti-CD40 and requirement for specific regulatory DNA motifs. A, FSDCs were transfected with 100 ng of pRLTK and 1 µg of either wild type pIL6-Luc651 or mutated pIL6-Luc651 constructs carrying mutation in the AP1, NF-B, and NF-IL6 sites. The transfected cultures were split into two flasks. 24 h later, one culture flask was incubated with 30 µg/ml anti-CD40 mAb 3/23 for a further 24 h, while the remaining flask was left untreated. Samples treated with 3/23 are depicted in black solid boxes, whereas untreated samples are in white. Luciferase activities were normalized to pRLTK activity and expressed as the mean ± S.E. of three independent transfection experiments. Statistical analysis was performed by Student's t test. *, **, and *** denote p < 0.05, 0.01, and 0.005, respectively. B, fold induction of the sample incubated with anti-CD40 mAb 3/23 versus the non-treated sample for each of the pIL6-Luc651 constructs.

Induction of NF-B by Anti-CD40-- To confirm a role for NF-B in the regulation of CD40-inducible IL-6 gene transcription, FSDC were co-transfected with the wild type IL-6 promoter construct and an expression vector for an IB- super-repressor protein (IBD) that lacks Ser³² and Ser³⁶ residues required for IKK-mediated phosphorylation and subsequent proteasome-mediated degradation (34). Overexpression of this mutated IB- therefore leads to capture of NF-B dimers in irreversibly inactive complexes. FSDC overexpressing the IBD displayed a reduction in both the basal and anti-CD40 induced IL-6 promoter activities relative to cells co-transfected with the control empty vector (fig 3A). When fold induction by anti-CD40 was determined we found that overexpression of IBD caused a diminution of inducible IL-6 promoter activity from 21.6-fold (control) to 7.7-fold (Fig. 3B). This level of inhibition was similar to the drop in fold-induction observed when the NF-B site of the IL-6 promoter was disrupted (Fig. 2B). Activation and DNA binding of NF-B are therefore required for induction of IL-6 gene transcription in CD40-stimulated FSDC. To determine whether there is a similar requirement in primary DCs we determined the effects of the NF-B inhibitor MG132 (36) on CD40 induction of IL-6 mRNA expression in BDMC. As shown in the representative gel in Fig. 3C inhibition of NF-B activation by MG132 completely blocked CD40 induced elevation of IL-6 transcript.

View larger version (20K): [in this window] [in a new window]   Fig. 3.   Induction of the IL-6 promoter requires activation of NF-B. A, FSDCs were transfected with 100 ng of pRLTK, 1 µg of wild type pIL6-Luc651, and 2 µg of IB trans-dominant negative (IBD) expression vector or pcDNA3 as control. The transfected cultures were split into two flasks. 24 h after transfection, one flask was incubated with 30 µg/ml anti-CD40 mAb 3/23 for 24 h while the remaining flask was left untreated. Luciferase activity was determined 48 h after transfection. Luciferase activities were normalized to pRLTK activity and expressed as the mean ± S.E. of three independent transfection experiments. Samples treated with 3/23 are depicted in black solid boxes, whereas untreated samples are in white. Statistical analysis was performed by Student's t test. *** denotes p < 0.005. B, fold induction of the samples incubated with anti-CD40 mAb 3/23 versus the non-treated samples as shown in Fig. 3A. C, mRNA was isolated from BMDCs which were either untreated () or incubated for 24 h with 30 µg/ml anti-CD40 mAb 3/23 together with either 5 µM MG132 dissolved in Me2SO or Me2SO alone. The mRNA was used to obtain first strand cDNA, which was used as a template in RT-PCR. cDNA species encoding murine IL-6 and -actin were amplified over 32 and 27 cycles in RT-PCR reactions using protocols described under "Materials and Methods." The gels shown are representative of at least two independent experiments. A 1-kilobase DNA ladder was run alongside the PCR products to confirm correct sizes of the amplified cDNA fragments.

We next determined if anti-CD40 treatment of FSDC induced NF-B DNA binding activities using a double stranded oligonucleotide carrying the NF-B binding sequence from the IL-6 promoter as an EMSA probe (fig 4A). Unstimulated FSDC (lanes 3, 5, 7, 9, and 11) expressed two NF-B DNA binding complexes, a weak low mobility complex (complex 2) and a more intense higher mobility interaction (complex 1). Both interactions were found to be sequence specific (data not shown) and were induced following a 24-h exposure of FSDC to anti-CD40 (compare lanes 2 and 3), however, the induction of complex 2 was more impressive than complex 1. For reasons not yet known the mobility of complex 1 was occasionally slightly altered in CD40-stimulated cells. To determine the protein components of the two CD40-inducible NF-B complexes we performed supershift/antibody interference experiments. Complex 2 was reactive with both anti-p50 (lane 4) and anti-p65 (lane 6) antisera, moreover incubation of pre-formed protein-DNA complexes with a combination of the two antibodies (lane 8) resulted in almost total interference of complex 2. By contrast, complex 1 was not reactive with either the p50 or p65 antisera either alone or in combination. From these data we conclude that the major inducible NF-B DNA binding activity of anti-CD40 stimulated FSDC is the classic p50:p65 heterodimer. Previous studies have shown that the NF-B DNA-binding site in the IL-6 promoter overlaps with a sequence that acts as a binding site for the transcriptional repressor CBF1 (also designated RBP-J) (37, 38). Since this overlapping sequence was included in our NF-B EMSA probe, we therefore investigated the possibility that NF-B complex 1 may be due to binding of CBF1. As precise nucleotides required for binding of p50:p65 and CBF1 have previously been identified we carried out EMSA using double stranded oligonucleotide probes carrying point mutations that disrupt binding of either p50:p65 or CBF1 (Fig. 4B). Loss of a nucleotide required for p50:p65 binding resulted in disrupted assembly of complex 2 but had no effect on complex 1, this confirms that p50:p65 heterodimers are the protein components of complex 2. In contrast, point mutations that prevent CBF1 binding had no effect on assembly of complex 2 but resulted in a loss of complex 1 formation. Confirmation that CBF1 was the protein component of complex 1 was obtained from supershift/antibody interference experiments in which we showed that an antisera raised against CBF1 could specifically interfere with complex 1 (Fig. 4C).

View larger version (53K): [in this window] [in a new window]   Fig. 4.   EMSA analysis of NF-B and CBF1 in anti-CD40 stimulated FSDC. A, nuclear extracts from control or FSDC cells treated with anti-mCD40 mAb 3/23 for 24 h were isolated and 2 µg used in EMSA with NF-B double stranded oligonucleotide probe. Two (1 and 2) specific DNA-protein complexes were assembled and are denoted by arrows. Supershift analysis was performed on control and treated samples using antisera recognizing p50 and p65 or JunB as a control. B, 2 µg of nuclear extracts from FSDC cells treated with anti-mCD40 mAb 3/23 for 24 h (as obtained in A) were incubated with double stranded NF-B oligonucleotide probe, or NF-B probe lacking p50/p65 or CBF1-binding sites. The nucleotide substitutions introduced into the wild type NF-B oligonucleotide to generate mutant oligonucleotides lacking p50/p65 or CBF1-binding sites are shown below the EMSA gel. C, 2 µg of nuclear extracts from FSDC cells treated with anti-mCD40 mAb 3/23 for 24 h (as obtained in A) were incubated with double stranded NF-B oligonucleotide probe and supershift analysis performed using antisera recognizing p50, p65, CBF1, or JunB as a control.

AP1 Is Induced by Anti-CD40 and Is Required for Stimulation of IL-6 Promoter Activity-- As mutagenesis of the AP1 site of the IL-6 promoter resulted in roughly a 50% drop in anti-CD40 stimulated transcription (Fig. 2, A and B) it was of interest to determine whether engagement of surface CD40 induces AP1 DNA binding activity in FSDC. EMSA analysis of protein-DNA complex formation was carried out using a double stranded oligonucleotide probe carrying the AP1-binding site from the IL-6 promoter. Fig. 5A shows that unstimulated FSDC express a weak AP1 DNA binding activity that was strongly induced in cultures treated for 16 h with anti-CD40. Ability of a 100-fold excess of unlabeled AP1 sites to compete for binding and lack of competition by a 100-fold excess of nonspecific (SP1 site) double stranded oligonucleotides confirmed that the AP1 protein-DNA complexes in FSDC were specific and saturable (Fig. 5A). As transcriptionally active AP1 complexes must contain a Jun (c-Jun, JunB, or JunD) factor either in homodimeric (Jun:Jun) or heterodimeric (Jun in partnership with a Fos family protein) forms, we used supershift/antibody interference to identify the Jun components of the CD40-inducible AP1 DNA binding activity of FSDC. As shown in Fig. 5B antisera recognizing c-Jun, JunB, and JunD reduced the intensity of AP1 DNA binding activity indicating that all three proteins may be present in the complex. However, JunB and JunD antisera not only reduced complex formation to a higher degree than the c-Jun antisera, but they also promoted the assembly of readily detectable supershift complexes. Hence JunB and JunD are likely to be the predominant Jun components of the induced AP1 complexes. We were also able to show that an antisera raised against c-Fos interfered with AP1 complex formation, hence anti-CD40 treatment may induce both Jun:Jun and Jun:Fos AP1 dimers in FSDC. Lack of supershift or interference in EMSA reactions incubated with anti-SP1 antisera confirmed specificity of the results obtained using the Jun and Fos antisera.

View larger version (70K): [in this window] [in a new window]   Fig. 5.   Induction of AP-1 activity by CD40 ligation. A, nuclear extracts from control or FSDC cells treated with anti-mCD40 mAb 3/23 for 16 h were isolated and 10 µg used in EMSA with AP1 double stranded oligonucleotide probe in presence of 100 M excess of unlabeled nonspecific oligonucleotide (Sp1) or unlabeled specific AP1 oligonucleotide. B, supershift analysis was performed on 3/23 mAb treated FSDC samples using antisera recognizing c-Jun, JunD, JunB, c-Fos, or Sp1 as a control. Supershift complexes are shown for extracts incubated with JunB and JunD antisera. Asterisks placed to the left of the supershift complexes are included to aid identification of these species. C, immunoblot analysis of JunD, JunB, and c-Jun protein expression was performed on crude cytoplasmic and nuclear extracts from control and FSDCs treated with 3/23 mAb for 16 h. All gels are representative of three independent experiments. D, FSDCs were transfected with 100 ng of pRLTK, 1 µg of wild type pIL6-Luc651, and 2 µg of JunD dominant negative expression vector pRSV-JunD or pRSV as control. The transfected cultures were split into two flasks and after 24 h one flask was incubated with 30 µg/ml anti-CD40 mAb 3/23 while the remaining flask was left untreated. Luciferase activity was determined 48 h after transfection. Luciferase activities were normalized to pRLTK activity and expressed as the mean ± S.E. of three independent transfection experiments. Samples treated with 3/23 are depicted in black solid boxes, whereas untreated samples are in white. Statistical analysis was performed by Student's t test. ** denotes p < 0.01.

As changes in AP1 activity can be regulated by either transcriptional or post-translational events it was of interest to establish if anti-CD40 treatment of FSDC alters the expression of Jun proteins. Fig. 5C shows a Western blot analysis of Jun protein expression in the cytoplasmic and nuclear fractions of unstimulated () and anti-CD40 stimulated (+) FSDC. All three Jun factors were expressed in both the cytoplasm and nucleus of FSDC. The cytoplasmic pool of the Jun factors was unchanged upon stimulation with anti-CD40, by contrast nuclear levels of c-Jun were slightly elevated while nuclear JunB expression was strongly induced. Confirmation of the requirement for Jun activity in the IL-6 promoter response to anti-CD40 treatment was obtained by co-transfection of FSDC with the IL-6 promoter and an expression vector (RSV-JunD) for a dominant negative JunD protein. The mutant JunD protein expressed from this vector lacks a functional transactivation domain (27). As the different Jun proteins are able to interact with each other to form functional AP1 binding dimers, overexpression of the dominant negative JunD will sequester c-Jun, JunB, and JunD proteins into functionally inactive dimers. Fig. 5D shows that co-transfection of RSV-JunD was without effect on basal levels of IL-6 promoter activity but profoundly inhibited CD40-induced transcription.

Structural Requirements in the Cytoplasmic Domain of CD40 Required for Induction of IL-6 Promoter Activity-- Previous studies in B and T cell lines have determined specific amino acid sequences in the cytoplasmic tail of CD40 that are required for activation of intracellular signaling in response to engagement of the receptor (2, 14-21). To determine the structural features of the CD40 cytoplasmic domain required for induction of IL-6 gene transcription in FSDC we employed the following strategy. A panel of wild type and mutant (carrying deletions or point mutations in the cytoplasmic domain) human CD40 expression vectors were co-transfected into FSDC with the IL-6 promoter-luciferase vector. The transfected culture was then exposed for 24 h to LOB7.6, an anti-CD40 monoclonal antibody that specifically recognizes human CD40 (hCD40) and lacks species cross-reactivity. Fluorescence-activated cell sorter detection of transfected hCD40 was used to confirm that the different expression vectors generated quantitatively similar levels of immunoreactive cell surface hCD40 (data not shown). FSDC transfected with wild type hCD40 displayed a 5.3-fold induction of IL-6 promoter activity in response to LOB7.6 (Fig. 6A). However, in contrast cells either transfected with the promoter alone or with mutant CD40 expression vectors producing proteins that either lacked a cytoplasmic tail (hCD40KKV) or had the cytoplasmic domain from CD22 in place of the CD40 cytoplasmic domain were unable to induce IL-6 transcription in response to LOB7.6. These data show, as expected, that the cytoplasmic domain of CD40 is critical for signaling. Mutation of threonine 254 to a residue that is not a target for phosphorylation (hCD40T254E and hCD40T254A) dramatically reduced LOB7.6 stimulation of IL-6 promoter activity. However, hCD40 carrying a serine substitution at this residue retained an ability to induce IL-6 promoter activity in response to LOB7.6. Phosphorylated threonine 254 has been reported to be critical for recruitment of TRAF2, -3, and -5 in response to engagement of CD40 (15-18), our data therefore suggest a role for these adaptor proteins in the induction of IL-6 gene transcription. Construct hCD40262 lacks 15 amino acids (262-277) at the COOH-terminal end of hCD40, which includes critical binding sites for TRAF3 (Q263), TRAF5, and Jak3 but is not critical for TRAF2 binding (15, 16, 18, 39). This construct was able to support LOB7.6-induced IL-6 promoter activity albeit at a reduced level (60%) relative to the induction obtained with wild type hCD40. A construct in which both threonine 254 is mutated and the final 15 amino acids are deleted (hCD40T254A262) was as expected unable to support LOB7.6 induction of IL-6 gene transcription. These data suggest that neither TRAF3, TRAF5, nor Jak3 play an essential role in anti-CD40 stimulation of IL-6 gene transcription in FSDC and indicate that TRAF2 is likely to be a major signal transducer of this response.

View larger version (13K): [in this window] [in a new window]   Fig. 6.   Requirement for specific amino acid sequences in the cytoplasmic domain of CD40. A, 1 µg of wild type pIL6-651Luc was transfected into FSDC cells along with 100 ng of pRLTK and 2 µg of empty vector pcDNA3 or pcDNA3-derived expression vectors carrying cDNA cassettes for wild type hCD40, truncated hCD40 containing three remaining intracellular residues (hCD40KKV), hCD40 mutants carrying point mutations (hCD40T254A, hCD40T254E, and hCD40T254S), hCD40 with a point mutation and a deletion of carboxyl-terminal 15 amino acids (hCD40T254A262), hCD40 with 15 carboxyl-terminal amino acids deleted (hCD40262), or a fusion protein made up of hCD450 extracellular and transmembrane domains and hCD22 intracellular domain. The transfected cultures were split into two flasks, one flask was treated with 300 µg/ml anti-human CD40 mAb LOB7.6 for 24 h and the other was left untreated. 24 h later, cells were harvested and luciferase assays performed. Samples treated with LOB7.6 are depicted in black solid boxes, whereas untreated samples are in white. Luciferase activities were normalized to pRLTK activity and expressed as the mean ± S.E. of six independent transfection experiments. B, FSDC cells were transfected with 1 µg of IB-Luc, 100 ng of pRLTK and hCD40 expression vectors and treated as already described in Fig. 5A. Luciferase activities were normalized to pRLTK activity and expressed as the means ± S.E. of five independent transfection experiments.

Lee and colleagues (16) recently reported that TRAF2 mediates the induction of ICAM-1 in CD40 stimulated B cells via activation of NF-B and Jun-N-terminal kinase 1. To determine whether TRAF2 binding is also required for induction of NF-B by engagement of hCD40 in FSDC we co-transfected the panel of hCD40 expression vectors together with an IB- promoter-luciferase reporter construct. Activity of the IB- promoter is critically dependent on binding of NF-B, forming a negative feedback mechanism for NF-B activation in cells (40). Measurement of IB- promoter activity can therefore be used as a sensitive and specific monitor of NF-B activation. Overexpression of wild type hCD40, hCD40T254S, and hCD40262 gave rise to an elevation of basal IB- promoter activity, all three constructs also supported a strong induction of promoter activity in cells stimulated for 24 h with LOB7.6 (Fig. 6B). By contrast, FSDC transfected with the remaining mutant hCD40 constructs that disrupt TRAF2 binding in addition to TRAF3, TRAF5, and Jak3 displayed low basal levels of IB- promoter activity that were not inducible by LOB7.6.

Inhibition of TRAF2 Signaling Blocks CD40 Activation of IL-6 Gene Transcription-- RT-PCR was used to confirm that FSDC express TRAF2 and TRAF6 transcripts, with no detectable change in expression following anti-CD40 treatment (fig 7A). To help confirm a major role for TRAF2 in anti-CD40 stimulation of IL-6 gene transcription we determined the effects of overexpressing a dominant negative TRAF2 protein on IL-6 promoter function. Co-transfection of the IL-6 promoter-luciferase reporter construct with an expression vector for a dominant negative TRAF2 resulted in a complete inhibition of anti-CD40 stimulated transcription (Fig. 7B). By contrast overexpression of a dominant negative TRAF6 protein had only a minor effect on the responsiveness of the IL-6 promoter to anti-CD40 treatment (Fig 7C). We were also able to show that dominant negative TRAF2 blocked anti-CD40 induction of IB- promoter activity while again dominant TRAF6 had only a minor inhibitory effect (data not shown). These data indicate a critical requirement for TRAF2 mediated signaling events as part of the pathways that stimulate NF-B activity and IL-6 gene transcription in response to anti-CD40 treatment of FSDC.

View larger version (30K): [in this window] [in a new window]   Fig. 7.   Inhibition of anti-CD40 induced IL-6 promoter activity by dominant negative TRAF2. A, mRNA was isolated from FSDCs which were either incubated with 30 µg/ml anti-CD40 mAb 3/23, or left untreated for 24 h. The mRNA was used to obtain first strand cDNA, which was used as a template in RT-PCR reactions using protocols described under "Materials and Methods." Utilizing this method, cDNA species encoding murine TRAF2, TRAF6, and -actin were amplified over 35, 35, and 28 PCR cycles, respectively. The gels shown are representative of at least two independent experiments. A 1-kilobase DNA ladder was run alongside the PCR products to confirm correct sizes of the amplified cDNA fragments. B, FSDCs were transfected with 100 ng of pRLTK, 1 µg of IB-Luc, and 2 µg of TRAF2 dominant negative (TRAF2 DN) expression vector or empty control vector. The cultures were split into 2 and 24 h after the transfection one-half was incubated with 30 µg/ml anti-CD40 mAb 3/23 for 24 h. Luciferase activity was determined 48 h after transfection. C, FSDCs were transfected with 100 ng of pRLTK, 1 µg of IB-Luc, and 2 µg of TRAF6 dominant negative (TRAF6 DN) and processed as described for B. For both B and C, luciferase activities were normalized to pRLTK activity and expressed as the mean ± S.E. of three independent transfection experiments. Samples treated with 3/23 are depicted in black solid boxes, whereas untreated samples are in white. Statistical analysis was performed by Student's t test. *** denotes p < 0.005.

Prolonged Anti-CD40 Stimulation of FSDC Leads to Reduced Basal Expression of IL-6-- In the experiments we have described so far, FSDC were stimulated with anti-CD40 for only 24 h. Since it is possible that DCs may interact with CD40L bearing T cells for longer periods of time it was important to investigate the longevity of the IL-6 response. Fig. 8 shows an RT-PCR analysis of IL-6 mRNA expression in FSDC incubated for 24, 48, and 72 h in the absence and presence of the anti-mouse CD40 monoclonal antibody 3/23. As expected a 24-h stimulation of FSDC with 3/23 gave rise to a strong induction of IL-6 mRNA expression. However, this induction was terminated by 48 h and moreover was accompanied by an almost complete loss of IL-6 transcript relative to its basal level of expression detected in control unstimulated cells. After 72 h stimulation there was a slight but incomplete recovery of basal IL-6 mRNA expression. We conclude that sustained engagement of surface CD40 leads to a repression of IL-6 gene transcription. To establish a mechanism for this response we used EMSA to determine the time-dependent effects of anti-CD40 stimulation on NF-B DNA binding activities (Fig. 9A). Maximal induction of the p50·p65 complex was observed at 16 h of stimulation after which there was a modest but steady decline in the intensity of this complex. By contrast the CBF1 protein-DNA interaction remained at an elevated level after 48 h of stimulation. The effects of increased CBF1 expression on IL-6 promoter activity was tested by co-transfecting FSDC with the IL-6 promoter-luciferase reporter and an expression vector for CBF1. As shown in Fig. 9B, overexpression of CBF1 dramatically repressed both basal and anti-CD40 induced IL-6 promoter activity. We therefore suggest that decline in activation of p50:p65 NF-B coupled with prolonged elevation of CBF1 DNA binding activity may contribute to the reduced basal expression of IL-6 in FSDC stimulated with anti-CD40 for periods in excess of 24 h.

View larger version (53K): [in this window] [in a new window]   Fig. 8.   Induction of IL-6 gene transcription by anti-CD40 is a transient response. mRNA was isolated from control or FSDCs treated with anti-mCD40 mAb 3/23 for 24, 48, or 72 h. mRNA was used to obtain first strand cDNA which was used as a template in RT-PCR reactions using protocols described under "Materials and Methods." Utilizing this method, cDNA species encoding murine IL-6 and -actin were amplified. The gels shown are representative of at least two independent experiments. A 1-kilobase DNA ladder was run alongside the PCR products to confirm correct sizes of the amplified cDNA fragments.

View larger version (26K): [in this window] [in a new window]   Fig. 9.   Prolonged induction of CBF1 DNA binding activity and repression of IL-6 promoter function. A, 2 µg of nuclear extract isolated from FSDC cells treated with anti-mCD40 mAb 3/23 for 0, 2, 4, 6, 16, 24, and 48 h was used in EMSA with NF-B double stranded oligonucleotide probe. B, FSDCs were transfected with 100 ng of pRLTK, 1 µg of wild type pIL6-Luc651, and 2 µg of CBF1 expression vector pJH282 or empty vector pSG5. The cultures were split into two flasks and 24 h after transfection one flask was incubated with 30 µg/ml anti-CD40 mAb 3/23 for 24 h, while the remaining flask was left untreated. The cells were then harvested and luciferase assay performed. Samples treated with 3/23 are depicted in black solid boxes, whereas untreated samples are in white. Luciferase activities were normalized to pRLTK activity and expressed as the mean ± S.E. of three independent transfection experiments. Statistical analysis was performed by Student's t test. *** denotes p < 0.005.

Signaling Events Downstream of CD40 Are Conserved in DC2.4 and FSDC Cell Lines-- Having determined the intracellular signaling events involved in the induction of IL-6 gene transcription in 3/23-stimulated FSDC it was considered important to verify our findings in a second mouse bone marrow-derived DC cell line DC2.4. RT-PCR analysis of IL-6 expression revealed that although DC2.4 expressed a higher basal level of IL-6 mRNA than FSDC there was a significant induction of expression at 24 h of anti-CD40 stimulation that with further stimulation was reduced to below basal levels as observed with FSDC (data not shown). We then determined the role played by NF-B (Fig. 10A), AP1 (Fig. 10B), TRAF2 (Fig. 10C), TRAF6 (Fig. 10D), and CBF1 (Fig. 10E) in DC2.4. Treatment of DC2.4 with 3/23 for 24 h resulted in a reproducible 2-3-fold induction of IL-6 promoter activity, which is a weaker response than observed for FSDC. However, the effects of attenuating each of the five signaling molecules were similar between DC2.4 and FSDC. Inhibition of TRAF2 and NF-B resulted in a total inhibition of 3/23 induced transcription, by contrast expression of dominant negative TRAF6 had only a minor inhibitory effect. Expression of dominant negative JunD significantly reduced 3/23 induced transcription although this effect was not as pronounced as that observed in FSDC. Finally overexpression of CBF1 dramatically repressed basal and anti-CD40 inducible IL-6 promoter activity in DC2.4. These data therefore support the generality of our findings in FSDC for mouse DC lines.

View larger version (22K): [in this window] [in a new window]   Fig. 10.   Conservation of CD40 signaling events between two distinct mouse DC lines (FSDC and DC2.4). To confirm the generality of findings with FSDC a series of key experiments were repeated using the mouse DC line DC2.4. DC2.4s were transfected with 100 ng of pRLTK, 1 µg of wild type pIL6-Luc651wt; A, 2 µg of IB dominant negative (IB DN) expression vector or pcDNA3 empty vector as a control; B, 2 µg of JunD dominant negative (pRSV JunD) expression vector or pRSV empty vector as a control; C, 2 µg of TRAF2 dominant negative (TRAF2 DN) expression vector or pRK5 empty vector as a control; D, 2 µg of TRAF6 dominant negative (TRAF6 DN) expression vector or pcDNA3 empty vector as a control; and E, 2 µg of CBF1 dominant negative (pJH282) expression vector or pSG5 empty vector as a control. The transfected cultures were split into two flasks. 24 h after transfection, one flask was incubated with 30 µg/ml anti-CD40 mAb 3/23 for 24 h while the remaining flask was left untreated. Luciferase activity was determined 48 h after transfection. Luciferase activities were normalized to pRLTK activity and expressed as the mean ± S.E. of three independent transfection experiments. Samples treated with 3/23 are depicted in solid black boxes, whereas untreated samples are in white. Statistical analysis was performed by Student's t test. * and *** denote p < 0.05 and p < 0.005, respectively.

	DISCUSSION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Despite the emergence of DCs as key cellular players in the immune system, the signaling events that regulate DC function are poorly understood. In the present study we have made a detailed analysis of the molecular events that lead to transcriptional induction of IL-6 in DCs stimulated via the CD40 signaling pathway. We have shown that engagement of CD40 on DCs leads to a powerful, but transient induction of IL-6 mRNA expression. This induction was maximal at 24 h after addition of anti-CD40 to cultures and was followed by a rapid diminution of IL-6 transcript to levels that were less than those found in unstimulated cultures. By investigating the structural requirements at both the CD40 cytoplasmic tail and the IL-6 promoter, together with establishing changes in the activity of specific transcription factors, we have been able to determine the mechanisms underlying these CD40 stimulated responses in DCs.

The IL-6 promoter was weakly active in FSDC, as expected from the low but detectable level of IL-6 transcript found in both FSDC and primary BMDC. Anti-mouse CD40 mAb 3/23 stimulated a powerful induction of IL-6 promoter activity in FSDC, as did anti-human CD40 mAb when added to FSDC transfected with a human CD40 expression construct. These observations contradict an earlier study using the B cell line CH12.LX in which it was shown that while membrane-bound CD40L could induce IL-6 promoter activity and mRNA expression, anti-CD40 mAb could not (14). Another discrepancy between this latter study and ours is the role of NF-B, the transcription factor was apparently dispensable for CD40 activation of IL-6 induction in CH12.LX (14), yet was critical for CD40-induction of IL-6 promoter function in FSDC, DC2.4, and primary bone marrow-derived DCs. The precise reasons for these discrepancies are not known, however, it is possible that there are inherent differences in either the phenotype of the cell lines or the quality of the antibodies used in the two studies. Whatever these differences may be, our study clearly demonstrates that engagement of endogenous mouse CD40 or transfected human CD40 by specific antibodies can induce IL-6 promoter activity in FSDC. This induction was dependent on the presence of intact DNA-binding sites for NF-B and AP-1. Both basal and anti-CD40 inducible activities of the IL-6 promoter were regulated by NF-B. Furthermore, we were able to show that blockade of the activation of NF-B by the proteasome inhibitor MG132 resulted in a total inhibition of anti-CD40 induced IL-6 mRNA expression in primary BMDC. By contrast, AP-1 appeared to be mainly required for inducible IL-6 promoter activity, since mutation of the AP-1 site of the IL-6 promoter or overexpression of a dominant negative JunD protein only had a significant negative effect on the promoter in cells treated with anti-CD40.

Engagement of endogenous CD40 on FSDC by addition of mAb 3/23 resulted in a transient induction of AP-1 DNA binding activity that was maximal after 16 h of stimulation. A single, but diffuse AP-1 DNA-protein complex was induced by 3/23 and consisted of all three Jun proteins together with at least one Fos family protein, c-Fos. Examination of Jun protein expression revealed that the major alteration in 3/23 stimulated cells was elevated nuclear expression of JunB. Although we did not detect any significant changes in the expression of c-Jun or JunD, the presence of both these proteins in the nucleus of FSDC, together with our ability to detect them in the anti-CD40-induced AP-1 complex indicates that post-translational events probably regulate their activity in FSDC. Of relevance to this idea, it is well established that engagement of CD40 results in the activation of the Jun N-terminal kinases (JNKs), which in turn are able to attenuate c-Jun and JunD activities (2). Previous studies in B cells have shown that engagement of CD40 induces c-Jun, JunB, JunD, c-Fos, FosB, and Fra1 at either the mRNA or protein level (41-43). However, few studies have investigated CD40 mediated induction of AP-1 activity or Jun and Fos protein family expression in monocytes or DCs. Revy et al. (19) suggested that CD40 stimulation of human monocytes was associated with induction of NF-B but not AP-1. Hence it is possible that monocytes and DCs differ in their ability to activate AP-1 in response to engagement of CD40, however, confirmation of this idea requires detailed comparative studies that are beyond the scope of the present study. From our data we can conclude that CD40 signaling in FSDC leads to the activation of a variety of Jun (c-Jun, JunB, and JunD) containing AP-1 dimers. We can also conclude that these AP-1 dimers are transcriptionally active and in combination with NF-B and NF-IL-6 are able to stimulate the elevated levels of IL-6 gene transcription observed in anti-CD40 stimulated FSDC.

Activation of NF-B is a widely documented consequence of CD40 signaling and is known to be required for many CD40-induced changes in gene expression (2). There is also a wide literature concerning the role of TRAFs as mediators of CD40-induced NF-B activation, however, there is controversy regarding the requirement for specific TRAFs in this response (14-16, 18). Studies in 293 cells have shown that NF-B and JNK can be activated by overexpression of TRAF2, TRAF5, and TRAF6, by contrast TRAF1, TRAF3, and TRAF4 are unable to activate either NF-B or JNK when overexpressed (16). Our data suggest that TRAF2 is the critical mediator of anti-CD40 stimulated NF-B activity and IL-6 gene transcription in FSDC and DC2.4. We were able to rule out an essential role for TRAF3/5 heterodimers and Jak3 signaling by showing that a hCD40 protein lacking the most COOH-terminal 15 amino acids that are critical for binding these proteins (15, 16, 18, 39) had the ability to induce IB- and IL-6 promoter activities. By contrast a hCD40 protein carrying a single amino acid substitution T254A (hCD40T254A) that abolishes binding of TRAF2 in addition to TRAF3/5 and Jak3 (16, 39) was unable to induce IB- promoter activity. Furthermore, this mutant displayed a markedly reduced stimulation of IL-6 promoter activity in response to anti-CD40 (1.5-fold, compared with a 5-fold response with wild type hCD40). Our data are therefore in agreement with the report by Lee et al. (16), who showed that binding of TRAF3/5 and Jak3 was dispensable for CD40-induced activation of NF-B, JNK, and ICAM-1 promoter activity. However, other investigators have suggested that TRAF2 is dispensable for NF-B activation (15), moreover at least two independent groups have reported that hCD40 carrying the T254A mutation can support activation of NF-B (18, 44). These latter studies suggested a role for TRAF6 as a potent activator of CD40-induced NF-B activation since binding of TRAF6 does not require T254. The residual 1.5-fold induction of IB- promoter activity that we observed in anti-CD40 stimulated hCD40T254A transfected FSDC may be due to TRAF6 signaling. Tsukamoto and colleagues (17) recently showed that TRAF2 and TRAF6 link CD40 to NF-B via distinct signaling pathways. TRAF2 utilizes a pathway that requires activation of the NF-B-inducing kinase (NIK), by contrast TRAF6 is able to activate NF-B independently of NIK. Hence it is possible that the observed differences in the apparent requirement for TRAF2 or TRAF6 by different investigators could lie in the differential usage of the NIK-dependent and -independent signaling pathways. Our data, which include demonstration that dominant negative TRAF2 inhibits CD40 stimulation of NF-B activation and IL-6 gene transcription while dominant negative TRAF6 has only a minor effect on these responses, indicate that the TRAF2/NIK pathway may predominate for CD40 activation of NF-B and IL-6 gene transcription in DCs.

Analysis of NF-B DNA binding events induced by anti-CD40 provided a clue as to why induction of IL-6 was transient and was proceeded by a loss of basal expression. The NF-B site of the IL-6 promoter overlaps with a binding site for CBF1 which can repress NF-B-dependent transcription driven by p50:p65 heterodimers (37, 38). We found that anti-CD40 treatment of FSDC generated a prolonged elevation of CBF1 DNA binding while induction of p50:p65 binding was transient. Since overexpression of CBF1 was able to repress basal and anti-CD40 induced IL-6 promoter activity, we suggest that the prolonged stimulation of CBF1 activity and the short-lived activation of NF-B and AP-1² eventually results in a repression of IL-6 gene transcription. However, the rapid loss of IL-6 transcript between 24 and 48 h post-stimulation of cells also implies that IL-6 mRNA must be rapidly degraded in FSDC. The short half-life of the transcript coupled with repression of IL-6 promoter function by CBF1 is therefore the most likely explanation for the loss of IL-6 transcript in FSDC stimulated via CD40 for longer than 24 h. Transient induction of IL-6 in CD40 stimulated DCs may be of great physiological importance. DCs exposed to IL-6 acidify their endosomes, which results in altered antigen processing leading to priming of T cell responses against cryptic determinants (10). Prolonged autocrine stimulation of DCs by IL-6 could therefore result in the generation of anti-self immunity and propagation of autoimmune disease. Autocrine IL-6 also inhibits the tolerogenic function of CD8⁺ DC by down-regulating IFN-R expression and thereby reducing the ability of DC to metabolize tryptophan and initiate T cell apoptosis (11). It is therefore tempting to speculate that the transient induction of IL-6 expression by CD40 stimulated DCs enables activation of naive T cells but also protects against the generation of anti-self immunity. Further understanding of the regulatory events that control IL-6 gene transcription in DCs may lead to the development of experimental strategies for attenuating DC function in pathological conditions and in the production of vaccines.

	ACKNOWLEDGEMENTS

We thank David Brenner, Oliver Eickelberg, Martin Glennie, Ron Hay, Diane Hayward, Luke O'Neill, and Lawrence Young for their kind gifts of reporter vectors and expression constructs. We also thank Steve Lyons and Kenneth Rock for their help with obtaining the DC2.4 cell line.

	FOOTNOTES

^* This work was funded by Tenovus Cancer Research Charity and Medical Research Council Grants G9900951 and G9900297 (to D. A. M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^¶ To whom correspondence should be addressed: Liver Group, Division of Infection, Inflammation and Repair, Level D, Southampton General Hospital, Southampton SO16 6YD, United Kingdom. Tel.: 44-23-80796871; Fax: 44-23-80794154; E-mail: dam2@soton.ac.uk.

Published, JBC Papers in Press, March 8, 2002, DOI 10.1074/jbc.M109250200

² J. Mann and D. A. Mann, unpublished observations.

	ABBREVIATIONS

The abbreviations used are: DC, dendritic cells; IL, interleukin; IFN, interferon ; Jak3, Janus kinase 3; TRAF, tumor necrosis factor receptor-associated factor; BMDC, bone marrow-derived dendritic cells; RT, reverse transcriptase; mAb, monoclonal antibody; JNK, c-Jun NH₂-terminal kinase.

	REFERENCES

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				M. Skarica, T. Wang, E. McCadden, D. Kardian, P. A. Calabresi, D. Small, and K. A. Whartenby Signal Transduction Inhibition of APCs Diminishes Th17 and Th1 Responses in Experimental Autoimmune Encephalomyelitis J. Immunol., April 1, 2009; 182(7): 4192 - 4199. [Abstract] [Full Text] [PDF]

				B. P. Lawrence, M. S. Denison, H. Novak, B. A. Vorderstrasse, N. Harrer, W. Neruda, C. Reichel, and M. Woisetschlager Activation of the aryl hydrocarbon receptor is essential for mediating the anti-inflammatory effects of a novel low-molecular-weight compound Blood, August 15, 2008; 112(4): 1158 - 1165. [Abstract] [Full Text] [PDF]

				F. A. Blocki, S. Radhakrishnan, V. P. Van Keulen, K. L. Heckman, B. Ciric, C. L. Howe, M. Rodriguez, E. Kwon, and L. R. Pease Induction of a gene expression program in dendritic cells with a cross-linking IgM antibody to the co-stimulatory molecule B7-DC FASEB J, November 1, 2006; 20(13): 2408 - 2410. [Abstract] [Full Text] [PDF]

				X. Huang, T. Gordon, W. N. Rom, and R. B. Finkelman Interaction of Iron and Calcium Minerals in Coals and their Roles in Coal Dust-Induced Health and Environmental Problems Reviews in Mineralogy and Geochemistry, January 1, 2006; 64(1): 153 - 178. [Abstract] [Full Text] [PDF]

				J. Mann, C. N. Patrick, M. S. Cragg, J. Honeychurch, D. A. Mann, and M. Harris Functional Analysis of HIV Type 1 Nef Reveals a Role for PAK2 as a Regulator of Cell Phenotype and Function in the Murine Dendritic Cell Line, DC2.4 J. Immunol., November 15, 2005; 175(10): 6560 - 6569. [Abstract] [Full Text] [PDF]

				R. M. Andrade, M. Wessendarp, J.-A. C. Portillo, J.-Q. Yang, F. J. Gomez, J. E. Durbin, G. A. Bishop, and C. S. Subauste TNF Receptor-Associated Factor 6-Dependent CD40 Signaling Primes Macrophages to Acquire Antimicrobial Activity in Response to TNF-{alpha} J. Immunol., November 1, 2005; 175(9): 6014 - 6021. [Abstract] [Full Text] [PDF]

				N. Mizumoto, J. Gao, H. Matsushima, Y. Ogawa, H. Tanaka, and A. Takashima Discovery of novel immunostimulants by dendritic-cell-based functional screening Blood, November 1, 2005; 106(9): 3082 - 3089. [Abstract] [Full Text] [PDF]

				F. Oakley, J. Mann, S. Nailard, D. E. Smart, N. Mungalsingh, C. Constandinou, S. Ali, S. J. Wilson, H. Millward-Sadler, J. P. Iredale, et al. Nuclear Factor-{kappa}B1 (p50) Limits the Inflammatory and Fibrogenic Responses to Chronic Injury Am. J. Pathol., March 1, 2005; 166(3): 695 - 708. [Abstract] [Full Text] [PDF]

				M. Galgani, V. De Rosa, S. De Simone, A. Leonardi, U. D'Oro, G. Napolitani, A. M. Masci, S. Zappacosta, and L. Racioppi Cyclic AMP Modulates the Functional Plasticity of Immature Dendritic Cells by Inhibiting Src-like Kinases through Protein Kinase A-mediated Signaling J. Biol. Chem., July 30, 2004; 279(31): 32507 - 32514. [Abstract] [Full Text] [PDF]

				A. T. Larregina, A. E. Morelli, O. Tkacheva, G. Erdos, C. Donahue, S. C. Watkins, A. W. Thomson, and L. D. Falo Jr Highly efficient expression of transgenic proteins by naked DNA-transfected dendritic cells through terminal differentiation Blood, February 1, 2004; 103(3): 811 - 819. [Abstract] [Full Text] [PDF]

				M. J. Ruddy, G. C. Wong, X. K. Liu, H. Yamamoto, S. Kasayama, K. L. Kirkwood, and S. L. Gaffen Functional Cooperation between Interleukin-17 and Tumor Necrosis Factor-{alpha} Is Mediated by CCAAT/Enhancer-binding Protein Family Members J. Biol. Chem., January 23, 2004; 279(4): 2559 - 2567. [Abstract] [Full Text] [PDF]

				M. Bros, X.-L. Ross, A. Pautz, A. B. Reske-Kunz, and R. Ross The Human Fascin Gene Promoter Is Highly Active in Mature Dendritic Cells Due to a Stage-Specific Enhancer J. Immunol., August 15, 2003; 171(4): 1825 - 1834. [Abstract] [Full Text] [PDF]

				A. Puig-Kroger, O. Muniz-Pello, R. Selgas, G. Criado, M-A. Bajo, J. A. Sanchez-Tomero, V. Alvarez, G. del Peso, P. Sanchez-Mateos, C. Holmes, et al. Peritoneal dialysis solutions inhibit the differentiation and maturation of human monocyte-derived dendritic cells: effect of lactate and glucose-degradation products J. Leukoc. Biol., April 1, 2003; 73(4): 482 - 492. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 277/19/17125    most recent M109250200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mann, J. Articles by Mann, D. A. Search for Related Content PubMed PubMed Citation Articles by Mann, J. Articles by Mann, D. A. Social Bookmarking                      What's this?